Molecular classification of multiple myeloma
AssigneeErasmus University Medical Center Rotterdam
InventorPieter Sonneveld
Life of this patent
Estimating the term…
Abstract
The present invention is in the field of molecular diagnostics and relates to a method for classifying samples obtained from patients diagnosed with multiple myeloma into three newly defined clusters. The invention also relates to a method for determining the prognosis of an individual diagnosed with multiple myeloma as well as a method for the prediction of the response to treatment of an individual diagnosed with multiple myeloma.
Claims7
A method for determining the disease outcome or the prognosis of a subject diagnosed with multiple myeloma by classifying the subject into at least one of clusters NFκB or PRL3, the method comprising:
- of determining the expression level of certain genes in a sample isolated from the subject;
- and
- classifying the subject into cluster NFKB if at least two genes selected from the group consisting of CDC42, BCL10, IL8, GADD45B, NFKBIE and MIRN155 are overexpressed, or into cluster PRL3 if at least two genes selected from the group consisting of PRL3, PTPRZ1, SOCS3 and SMYD3 are overexpressed:
- wherein clusters NFκB and PRL3 correlate with an improved prognosis and a distinct response to therapy.
Dependencies are inferred from the claim text.